Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study - sprookjes - yvandenbroek - TriplyDB

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

http://www.wikidata.org/entity/Q24814804

about

Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report Statins research unfinished saga: desirability versus feasibility A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus Dyslipidemic drugs in metabolic syndrome.Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial A systematic review and meta-analysis on the therapeutic equivalence of statins.Metabolomics and ischaemic heart disease.Statins and venous thromboembolism: do they represent a viable therapeutic agent?Do people with diabetes need statins?Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.

P2860

Q24634840-6FD57238-7236-4A21-9BA5-B1A78EBC66DD Q24647828-885F8AF9-BF86-4F22-8547-DC94A49374E9 Q24811267-E0D4248C-A037-4963-9896-694633F5A3B1 Q33616073-1C074481-3497-4BE7-9BE1-83F5E8811A49 Q33890208-578C98CC-FE3D-4D3C-96AC-67609EB06EB0 Q34636887-62EAF81C-8536-431F-9BEE-86E6769C420E Q34757030-FC6CFCA2-8F42-4961-949C-8C9711BE1340 Q37016008-D02FB01F-F244-4F57-B10C-30E20C459E28 Q37700760-99CC8105-8673-49DE-BC8C-F2520C13B865 Q37747986-DDE102AD-92F1-42FA-A447-5B80116849E2 Q38060209-259CB3E1-D104-4A6D-84D5-E7068BA0BBCD Q39445730-44366955-D1D8-4DB4-B349-CEBADB0081BD Q46453250-953C301C-0518-41E4-8095-7C33BF7E7B5B Q46697563-170ADDFB-9FD5-4CE7-9617-C12D1CE11221 Q46879881-52E20540-9D15-4883-BE2E-D73783D8207F Q50108375-8BF70C50-2D8B-48DC-AF0B-4F6B0E7231C2 Q51304354-D3A73E7E-33CE-4B8C-AD32-42608FD03D6E

P2860

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

http://www.wikidata.org/entity/Q24814804

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Comparison of rosuvastatin and ...... results from the URANUS study

@ast

Comparison of rosuvastatin and ...... results from the URANUS study

@en

Comparison of rosuvastatin and ...... results from the URANUS study

@nl

type

label

Comparison of rosuvastatin and ...... results from the URANUS study

@ast

Comparison of rosuvastatin and ...... results from the URANUS study

@en

Comparison of rosuvastatin and ...... results from the URANUS study

@nl

prefLabel

Comparison of rosuvastatin and ...... results from the URANUS study

@ast

Comparison of rosuvastatin and ...... results from the URANUS study

@en

Comparison of rosuvastatin and ...... results from the URANUS study

@nl

P1433

Q24814804-145A22FC-C844-4DF2-B29E-CB27F7685F42

P1476

Q24814804-8D8AA32F-706C-4876-9A9D-759DBF5CE9AF

P2093

Q24814804-DC9DC29E-844C-4B5A-84DC-BD0F8C0463F7

Q24814804-F8AF9A23-DDFF-4CFD-B1EB-66A6BA125169

P2860

Q24814804-0C506DB7-5B40-402B-8E99-D5CF72F0F068

Q24814804-0C795788-47E5-4FA8-B5C5-4850668F6C46

Q24814804-0C7E800A-ABD2-4C81-AF41-BABF6D0FF47A

Q24814804-0D8AAEB7-FFAF-474E-967A-3284BEA013D2

Q24814804-1304184F-BF18-4865-918F-89ABC9B4FC65

Q24814804-13FFD75A-1257-42E1-921E-334D1BF3FA5C

Q24814804-1F194A94-3450-40BC-B031-FCDCA6CAE057

Q24814804-348EFDF9-C57F-48CB-A1BC-B538A20C58D3

Q24814804-43195A8B-8760-465D-9C22-7B557BD585CE

Q24814804-48B13334-4227-4B04-BD24-1131118B3175

P2888

Q24814804-A68C06D1-7690-42CD-9334-7C07BD9AAE3A

P304

Q24814804-2BA376C5-CC0B-4E55-A003-2A813D10464A

P31

Q24814804-7803DD67-899D-4A2F-B149-39558645A9D6

P356

Q24814804-D0185C98-9DFB-46AC-A28A-AC5B5E41471A

P407

Q24814804-AB76981B-31A5-4E71-BF0E-3752A5545B92

P433

Q24814804-FAE9E38A-17B4-4277-8349-17F50BD3750C

P478

Q24814804-5E624675-D240-41B5-AEAE-A64771DA1E4C

P577

Q24814804-43915ABC-CC52-47E0-B569-C434FFBFACBE

P5875

Q24814804-1A58A11D-F7E3-42BD-89BA-8B9B804E15CA

P6179

Q24814804-26783D18-AD2D-4B3B-85F8-D301C408340B

P698

Q24814804-A32FA7DF-C948-49F2-9E1E-0CEE4EC7419C

P921

Q24814804-34987388-BA2D-49A3-BE59-B060D7FA81B2

P932

Q24814804-EE15E1E3-5213-40BE-93D4-B094B9100C5E

P356

P1433

Cardiovascular Diabetology

P1476

Comparison of rosuvastatin and ...... results from the URANUS study

@en

P2093

Annica Siewert-Delle

http://www.w3.org/2001/XMLSchema#string

Christian Berne

http://www.w3.org/2001/XMLSchema#string

P2860

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention

Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

P2888

P304

7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-4-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7807391

http://www.w3.org/2001/XMLSchema#string

P6179

1001766949

http://www.w3.org/2001/XMLSchema#string

P698

15935095

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

1166567

http://www.w3.org/2001/XMLSchema#string